Research Reports Coverage on Biotech Stocks -- Biogen, ImmunoGen, Jazz Pharma, and Cempra

Sep 07, 2016, 08:05 ET from Chelmsford Park SA

NEW YORK, September 7, 2016 /PRNewswire/ --

The Biotech arena took a beating at the start of this year, but recent major takeovers have started drawing investors' interests back toward the industry. shifts investors' attention to these four equities and see if they are positioned for long-term growth: Biogen Inc. (NASDAQ: BIIB), ImmunoGen Inc. (NASDAQ: IMGN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Cempra Inc. (NASDAQ: CEMP). These stocks research reports can be downloaded now by simply registering for free at:


Cambridge, Massachusetts headquartered Biogen Inc.'s stock finished Tuesday's session 0.93% lower at $310.67 with a total volume of 1.71 million shares traded. The Company's shares have advanced 22.86% over the previous three months and 1.41% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.77% and 13.22%, respectively. Furthermore, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders, have a Relative Strength Index (RSI) of 58.80.

On September 1st, 2016, Biogen announced that aducanumab, its investigational treatment for early Alzheimer's disease, was granted Fast Track designation by the U.S. Food and Drug Administration. The company stated that, Aducanumab is currently being evaluated in two global Phase 3 studies, ENGAGE and EMERGE, which are designed to evaluate its safety and efficacy in slowing cognitive impairment and the progression of disability in people with early Alzheimer's disease.

Yesterday, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'. Your complete research report on BIIB can be retrieved for free at:


On Tuesday, shares in Waltham, Massachusetts headquartered ImmunoGen Inc. ended the session at $2.86, up 4.00%. The stock recorded a trading volume of 1.48 million shares. The Company's shares are trading 3.85% below their 50-day moving average. Moreover, shares of ImmunoGen, which develops targeted anticancer therapeutics, have an RSI of 44.35.

As per notes filed with the SEC on August 25th, 2016, ImmunoGen issued a press release on August 4th, 2016, to announce its financial results for the quarter and year ended June 30th, 2016. The company reported a net loss of $143.7 million for the year, or $1.65 per share. Due to information that became available after the press release related to a potential liability to a contract manufacturer for cancellation of a future manufacturing slot, an additional expense accrual was required and the company's financial results have been adjusted. The company's net loss has been increased to $144.8 million, or $1.67 per share, and will be reported as such in its 10-K filing. IMGN free report is just a click away at:

Jazz Pharma  

Dublin, Ireland headquartered Jazz Pharmaceuticals PLC's stock ended yesterday's session 0.48% higher at $121.42 with a total volume of 572,706 shares traded. Shares of the Company, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, are trading 11.97% below their 200-day moving average. The stock has an RSI of 22.88.

On August 9th, 2016, Jazz Pharma reported that net product sales increased 14% in Q2 2016 compared to the same period in 2015, due to higher net product sales of Xyrem, Erwinaze, and Defitelio. GAAP net income attributable to Jazz Pharma for Q2 2016 was $111.3 million, or $1.80 per diluted share, compared to $88.1 million, or $1.40 per diluted share, for Q2 2015.

On August 10th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $195 a share to $185 a share. Sign up for your complimentary research report on JAZZ at:


At the close, shares in Chapel Hill, North Carolina headquartered Cempra Inc. recorded a trading volume of 962,508 shares, which was above their three months average volume of 731,660 shares. The stock finished 3.26% higher at $22.83. The Company's shares have surged 17.80% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 13.95% and 12.21% respectively. Furthermore, shares of Cempra, which focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America, have an RSI of 59.62.

On August 23rd, 2016, Cempra announced that the European Medicines Agency (EMA) has validated the company's marketing authorization application (MAA) seeking approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired bacterial pneumonia. The EMA's validation of the MAA confirms that the submission is complete and formally starts the review process. The EMA's Committee for Medicinal Products for Human Use will now begin their assessment of solithromycin through the centralized review procedure. Register for free on and download the latest research report on CEMP at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA